| General Information | |
|---|---|
| ZINC ID | ZINC000040411523 |
| Molecular Weight (Da) | 507 |
| SMILES | CCCC(CCC)C(=O)NC(=O)c1nn(-c2ccc(Cl)cc2Cl)c(-c2ccc(Cl)cc2)c1C |
| Molecular Formula | C25Cl3N3O2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 134.495 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 33 |
| LogP | 8.387 |
| Activity (Ki) in nM | 26.9153 |
| Polar Surface Area (PSA) | 63.99 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | + |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.07 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.32 |
| Ilogp | 4.26 |
| Xlogp3 | 8.03 |
| Wlogp | 7.28 |
| Mlogp | 5.61 |
| Silicos-it log p | 7.2 |
| Consensus log p | 6.48 |
| Esol log s | -7.76 |
| Esol solubility (mg/ml) | 0.00000876 |
| Esol solubility (mol/l) | 1.73E-08 |
| Esol class | Poorly sol |
| Ali log s | -9.23 |
| Ali solubility (mg/ml) | 0.0000003 |
| Ali solubility (mol/l) | 5.92E-10 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.88 |
| Silicos-it solubility (mg/ml) | 6.62E-08 |
| Silicos-it solubility (mol/l) | 1.31E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.69 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.52 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.326 |
| Logd | 5.736 |
| Logp | 6.926 |
| F (20%) | 0.001 |
| F (30%) | 0.004 |
| Mdck | - |
| Ppb | 99.47% |
| Vdss | 1.192 |
| Fu | 1.62% |
| Cyp1a2-inh | 0.117 |
| Cyp1a2-sub | 0.798 |
| Cyp2c19-inh | 0.841 |
| Cyp2c19-sub | 0.41 |
| Cl | 2.35 |
| T12 | 0.041 |
| H-ht | 0.41 |
| Dili | 0.958 |
| Roa | 0.888 |
| Fdamdd | 0.161 |
| Skinsen | 0.065 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.028 |
| Bcf | 3.17 |
| Igc50 | 5.218 |
| Lc50 | 6.099 |
| Lc50dm | 6.165 |
| Nr-ar | 0.053 |
| Nr-ar-lbd | 0.008 |
| Nr-ahr | 0.811 |
| Nr-aromatase | 0.868 |
| Nr-er | 0.698 |
| Nr-er-lbd | 0.058 |
| Nr-ppar-gamma | 0.905 |
| Sr-are | 0.901 |
| Sr-atad5 | 0.055 |
| Sr-hse | 0.335 |
| Sr-mmp | 0.948 |
| Sr-p53 | 0.941 |
| Vol | 485.126 |
| Dense | 1.041 |
| Flex | 0.526 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 3 |
| Qed | 0.349 |
| Synth | 2.575 |
| Fsp3 | 0.32 |
| Mce-18 | 21 |
| Natural product-likeness | -1.07 |
| Alarm nmr | 0 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |